莱美药业：子公司四川瀛瑞的纳米炭铁混悬注射液二期临床进展顺利

Core Viewpoint - The company announced that its subsidiary, Sichuan Yingrui, is making steady progress in the clinical trials of its nano carbon iron suspension injection (CNSI-Fe) [1] Group 1 - The second phase of clinical trials for CNSI-Fe is progressing smoothly [1] - The company will strictly adhere to relevant regulations regarding information disclosure about the product's development [1]